Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated ...

Eli Lilly’s (NYSE: LLY) market isn’t out of the weeds yet ... grew by 17% and will accelerate in Q4 due to the latest ...

A wealthy tech boss is under fire over his unusual side-hustle - peddling puppies that animal welfare groups say are bred in cruel, factory-like conditions.

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Driven by new product successes and strategic investments, Eli Lilly and Co (LLY) reports a 42% revenue increase, setting a ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

LLY had $11.4 billion in revenue for the quarter (up 20% versus Q3 figures from last year), with a net income of $970 million ...